UNSPSC 51293608: Iprindole

This classification denotes a tricyclic antidepressant with the molecular formula C19H28N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69U0IKR8FP, chemically known as 5h-cyclooct(b)indole-5-propanamine, 6,7,8,9,10,11-hexahydro-n,n-dimethyl- but generally known as iprindole, which bears US NIH Compound Identifier 21722. European Medicines Agency schedules Iprindole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08279MIG.

UNSPSC 51293608 Iprindole is a Commodity code. The code nominally classifies a specific pharmaceutical agent, but recent state and local procurement activity under this code does not reflect purchases of iprindole itself. Instead, issuing bodies are using the code to tag solicitations for naloxone (an opioid-reversal agent), generic multi-source pharmaceuticals distributed through cooperative purchasing, and pharmacy benefit program infrastructure. The mismatch between the code's name and actual procurement scope suggests that state and local procurement offices are applying this Commodity code as a catch-all for pharmaceutical acquisition without strict adherence to the specific active ingredient. Work being solicited includes the supply of finished pharmaceutical products (naloxone, OTC drugs, generic multi-source medications) with accompanying logistics and cold-chain management, enrollment in authorized wholesale distribution networks, compliance with cGMP and Drug Supply Chain Security Act requirements, and in one case, exploratory contracting models for direct-to-manufacturer pharmacy benefit arrangements. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance). The code shows limited and geographically dispersed recent activity.

Recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional PBM and GPO channels, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers with products effective July 1, 2026. Geographic spread includes Florida, Texas, Minnesota, and Oregon. Recent activity is light and scattered across distinct procurement models—direct county purchase, state exploratory market research, and multistate cooperative contracting—with no standout repeat buyers evident in the recent opportunities block.